← Eichor
Condition: Hepatic Chemotherapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hepatic Chemotherapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Pa
Phase 3 · 60 location(s) · ECOG-ACRIN Cancer Research Group · NCT05863195HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06333561DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06641713Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unrese
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT06406634Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
Phase 2 · 1 location(s) · Michael J Cavnar, MD · NCT07201519Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced
Phase 2 · 1 location(s) · West China Hospital · NCT06859684FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of P
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07012798HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resecti
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06313203Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein T
Phase 2 · 1 location(s) · First Hospital of China Medical University · NCT07483359Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
Phase 2/Phase 3 · 11 location(s) · UNICANCER · NCT06904170PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
Phase 2 · 1 location(s) · West China Hospital · NCT06742424Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcin
Phase 2 · 1 location(s) · Northern Jiangsu People's Hospital · NCT07337421Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06041477Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05751343Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Poten
Phase 2/Phase 3 · 2 location(s) · Shanghai Zhongshan Hospital · NCT06796803Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Phase 1/Phase 2 · 2 location(s) · Zhejiang Cancer Hospital · NCT06741020Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Trac
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT07636798Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06904183Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06031285Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Phase 2 · 4 location(s) · Insel Gruppe AG, University Hospital Bern · NCT06274879HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectabl
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06244225QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07327788Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Phase N/A · 2 location(s) · Ze-yang Ding, MD · NCT05713994HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Phase 2 · 3 location(s) · Sun Yat-sen University · NCT06737913HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Phase 3 · 1 location(s) · Binkui Li · NCT07594340Additional Chemotherapy Administered Directly Into the Liver Using a Chemo Pump in Patients With Bile Duct Cancer Inside
Phase 2 · 1 location(s) · Erasmus Medical Center · NCT06888063Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First L
Phase 3 · 49 location(s) · Federation Francophone de Cancerologie Digestive · NCT02885753Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversio
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07560488HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic
Phase N/A · 1 location(s) · First Hospital of China Medical University · NCT06632093
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.